Figure 3.

Greco et al.³⁰ formulated liposomal HDTs for tuberculosis. (A) Schematic of asymmetric liposome fabrication⁶⁴ used to create apoptotic body-like liposomes (ABL) carrying phosphatidic acid (PA) inside and phosphatidylserine on the outside. (B) Intracellular bacterial load in macrophages post treatment with test (ABL/PA) and control ((ABL/phosphatidylcholine (PC)), (PC/PA), (PC/PC)) liposomal formulations demonstrates the role of PA in inhibiting intracellular M.tb growth. (C) Bacterial organ load significantly drops with intranasal ABL/PA treatment in lungs, while bacterial clearance in spleen and liver requires systemic INH treatment. *P < 0.001, **P < 0.05, #P = not significant in comparison with infected control mice that received no treatment.³⁰